CEO | Zhongao Biomedical Technology (Guangdong) Co., Ltd | Australia
Dr. Guoying Ni is an esteemed researcher specializing in the tumor microenvironment and immunotherapy. With a PhD from Griffith University School of Medicine, Australia, Dr. Ni has dedicated nearly 15 years to groundbreaking research at the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Dr. Ni’s research has led to significant advancements, including the application of nanostructured graphene oxide for targeted immunotherapy and the discovery of tumor-inhibiting properties of Caerin peptides from Australian tree frogs.
Profile
Scopus
Strengths for the Awards
- Extensive Research Experience – Dr. Ni has been engaged in tumor microenvironment and immunotherapy research for nearly 15 years across multiple institutions in Australia and China.
- Innovative Contributions – Key contributions include using nanostructured graphene oxide for IL-10R antibody delivery and discovering the tumor-inhibitory effects of Caerin peptides.
- High-Impact Publications – With nearly 60 research papers published in prestigious journals (Q1-ranked, impact factor over 12), Dr. Ni’s work demonstrates strong academic influence.
- Funding and Grants – Dr. Ni has secured over 20 million RMB in research funding, showing recognition and support from funding bodies.
Education 🎓
Dr. Ni obtained a PhD from Griffith University School of Medicine, Australia. During this time, extensive research in immunotherapy and molecular biology laid the foundation for Dr. Ni’s expertise in cancer treatment methodologies.
Experience 🌟
Dr. Ni has held pivotal research positions at multiple prestigious institutions, including the University of Wollongong, Griffith University, University of the Sunshine Coast, and Guangdong Pharmaceutical University. Key contributions include developing a novel antibody delivery system using graphene oxide nanoparticles and evaluating anti-IL-10R antibody peptides in vitro and in vivo. Additionally, Dr. Ni has over eight years of experience supervising master’s and PhD students across Australia and China.
Dr. Ni’s research focuses on tumor immunotherapy, nanomedicine, and molecular oncology. Notable areas of interest include:
- Graphene oxide as a targeted antibody delivery system
- Anti-IL-10R therapy in cancer treatment
- Caerin peptides for tumor suppression and immune response activation
- Peptide-based immunotherapies for clinical applications
Awards & Honors 🏆
- 2022-2023: DVCR/A Launch Research Grant/Award, University of the Sunshine Coast, Australia
- 2016-2017: HDR Merit Research Grant, Griffith University, Australia
- 2013: GRPRS Scholarship and HDR Scholarship, Griffith University
- Visiting Professor: Guangdong Pharmaceutical University, First People’s Hospital of Foshan, Guangdong Province
Publications 📄
- Title: Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages
- Authors: Fu, Q.; Luo, Y.; Li, J.; … Ni, G.; Wang, T.
- Publication Year: 2024
- Citations: 0
- Title: Caerin 1.9–Titanium Plates Aid Implant Healing and Inhibit Bacterial Growth in New Zealand Rabbit Mandibles
- Authors: Long, Y.; Duan, X.; Fu, Q.; … Liu, X.; Yang, W.
- Publication Year: 2024
- Citations: 0
- Title: Host-defence caerin 1.1 and 1.9 peptides suppress glioblastoma U87 and U118 cell proliferation through the modulation of mitochondrial respiration and induce the downregulation of CHI3L1
- Authors: Wang, Y.; Zhong, F.; Xiao, F.; … Wang, T.; Zhang, W.
- Publication Year: 2024
- Citations: 1
- Title: Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides
- Authors: Fu, Q.; Luo, Y.; Li, J.; … Wang, T.; Ni, G.
- Publication Year: 2024
- Citations: 0
- Title: Proteomic analysis of anti-MRSA activity of caerin 1.1/1.9 in a murine skin infection model and their in vitro anti-biofilm effects against Acinetobacter baumannii
- Authors: Zhang, P.; Tang, S.; Fu, Q.; … Chen, G.; Liu, X.
- Publication Year: 2023
- Citations: 2
- Title: Single-nucleus RNA sequencing and deep tissue proteomics reveal distinct tumour microenvironment in stage-I and II cervical cancer
- Authors: Liu, X.; Ni, G.; Zhang, P.; … Yuan, S.; Wang, T.
- Publication Year: 2023
- Citations: 10
- Title: Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria
- Authors: Cavallazzi Sebold, B.; Li, J.; Ni, G.; … Liu, X.; Wang, T.
- Publication Year: 2023
- Citations: 6
- Title: Experimental study of 131I-caerin 1.1 and 131I-c(RGD)2 for internal radiation therapy of esophageal cancer xenografts
- Authors: He, T.; Du, J.; Zhu, K.; … Zhang, P.; Yuan, J.
- Publication Year: 2023
- Citations: 2
- Title: Degradation of differently processed Mg-based implants leads to distinct foreign body reactions (FBRs) through dissimilar signaling pathways
- Authors: Liu, X.; Chen, G.; Zhong, X.; … Gao, M.; Li, H.
- Publication Year: 2023
- Citations: 5
- Title: PEGylated IL-10: Clinical Development in Cancer Immunotherapy, Where to Go?
- Authors: Cavallazzi Sebold, B.; Ni, G.; Li, J.; … Liu, X.; Wang, T.
- Publication Year: 2023
- Citations: 3
Conclusion 🎉
Dr. Guoying Ni is a trailblazer in tumor immunotherapy and nanomedicine. With numerous research contributions, multiple prestigious awards, and collaborations with globally recognized scientists, Dr. Ni continues to push the boundaries of medical research to develop innovative cancer treatments. Through dedication and expertise, Dr. Ni’s work is making a significant impact on the future of cancer immunotherapy.
